United States Food and Drug Administration (USFDA) has successfully completed an unannounced inspection at Rubicon Research’s R&D facility located at Concord, Ontario, Canada, from April 20, 2026 to April 24, 2026. The inspection concluded without any Form-483 being issued.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
| Company Name | CMP |
|---|---|
| Wework India Mgmnt. | 736.50 |
| Rubicon Research | 1381.65 |
| Aegis Vopak Terminal | 294.55 |
| Mallcom (India) | 1017.65 |
| Inducto Steel | 60.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: